📣 Register NOW for the First #HFAJournalClub 📰

The PUSH-AHF Trial
🗓️ 5 June 2024
🕖 18:00 CET
📩 SEND YOUR QUESTIONS before the event

Made by and for the #HFA_Young

🔗esc365.escardio.org/event/1635

#HFA_ESC European Society of Cardiology #HFA_Young

Jozine ter Maaten Chris Kapelios Henrike Arfsten Antonio Cannata'

Twenty Years of Get With The Guidelines-Stroke: Celebrating Past Successes, Lessons Learned, and Future Challenges

ahajournals.org/doi/10.1161/ST…

AHA Science AHA Research American_Stroke

Wayne highlighted the critical importance of clear communication and actively involving caregivers in heart failure care. Their role is essential in supporting patients and ensuring better outcomes. #HFupdate #HeartFailure #Caregivers #Communication '

A moving and impactful opening plenary at CHFS #HFUpdate : gaps/access, providing culturally inclusive care, recognizing the importance of language and resiliency and successful implementation strategies to GDMT.

Hearing the lived experience from Mr. Standvik was

Day 2 of #HFUpdate starting with The Rainbow Session Co-Chaired by Shelley Zieroth & Marco Metra . Key message from Sheldon Tobe
'why add months to life when we can add years to life. Start medication early...' #heartfailure

Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at #8HID and published at the Journal Metabolism.

#HID24 #CME #CKM #8thHeartinDiabetes #MedEd #HID2024 Steve Greene Erin D. Michos, M.D. Javed Butler

Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at #8HID and published at the Journal Metabolism.

#HID24 #CME #CKM #8thHeartinDiabetes #MedEd #HID2024 Steve Greene Erin D. Michos, M.D. Javed Butler

Terrific work led by Duke Cardiology Fellows Mark Kittipibul MD

Many 🏥 and #HF patients continue to struggle w readmissions.

Across #RCTs , #SGLT2i significantly reduce both HF and **all-cause** hospitalization, regardless of EF

🔗jacc.org/doi/10.1016/j.…

Duke Clinical Research Institute Muthu Vaduganathan

Hot on the heels of FLOW:

What are the effects of SGLT2i on clinical outcomes with and without GLP-1RA? 🧵

Over 3,000 patients receiving GLP-1RA at baseline in SGLT2i Trialists' Consortium (SMART-C)

#ERA24 ERA - European Renal Association

#HFupdate Day 1! We start off the day with a Call to Action from HeartLife Foundation announcing a Bill has been tabled to address #heartfailure care in 🇨🇦. 🙏Marc Bains 𝐉𝐈𝐋𝐋𝐈𝐀𝐍𝐍𝐄 𝐂𝐎𝐃𝐄, 𝐏𝐇.𝐃 🍁☘️🌻🧡 for your leadership Senator Yonah Martin + Senator F. Gigi Osler for your support. Much work to do #advocacy

Steve Greene speaks at #HFUpdate on implementation of #GDMTworks across the continuum of ejection fraction. CHFS HeartLife Foundation Muthu Vaduganathan Anu Lala-Trindade Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Nosheen Reza, MD Emer Joyce Yas Moayedi Mena g

Getting ready to for great opening session CHFS meeting! Time to talk #GDMTworks

Shelley Zieroth Justin Ezekowitz Duke Clinical Research Institute

No increased risk of AKI with semaglutide

Note the heart failure adverse events…

#era24 ERA - European Renal Association

The FLOW trial results are live at @nejm as well

#ERA24

nejm.org/doi/full/10.10…

Primary composite kidney ✅
CV Death✅
All cause death ✅
GFR slope ✅
First MACE ✅
Kidney specific composite ✅

Effects of semaglutide on CV outcomes in FLOW presented by Kenneth Mahaffey

18% reduction in MACE

20% reduction in all cause mortality

NNT 39 to prevent one death over 3 years

#erakidney ERA - European Renal Association

#ERA24

FLOW trial

Amazing

20% lower risk of overall death

18% lower risk of CV death, non-fatal Mi or non-fatal stroke
James Januzzi Jr MD

Do not miss the #ESC_HFA scientific statement on how to tackle clinical inertia in #HF . Pragmatic suggestions on implementing GDMT in clinical practice onlinelibrary.wiley.com/doi/full/10.10… European Society of Cardiology Journals EJHF Editor-in-Chief HFAPresident Henry Han Steve Greene
Karolinska Institutet Karolinska Univ.sjuk Gregg Fonarow MD

Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure

Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization.

Dapagliflozin associated with enhanced diuresis among patients with AHF

sciencedirect.com/science/articl…

RENAL LIFECYCLE Trial: Efficacy and safety of dapagliflozin 10 mg vs placebo #Nephpearls #NephJC

✅ eGFR <25
✅ Patients on dialysis with residual diuresis >500 mL/24-hour
✅ Kidney transplant recipients with an eGFR </=45

📌 PRIMARY ENDPOINT: Composite end point of kidney

Fantastic Duke Cardiology grands rounds by future EP Ilya Shadrin, MD/PhD on his research and Insights into Conduction System Pacing! Duke Heart Dan Friedman Jonathan Piccini, MD, MHS Camille Frazier-Mills, MD MHS Larry R. Jackson II, MD, MHSc Kevin L. Thomas